首页> 美国卫生研究院文献>Gut >Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A
【2h】

Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A

机译:在SHU 508A的门静脉和特定晚期通过超声造影增强组织学证实的肝肿瘤的特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: Ultrasound is reported to be relatively unreliable in the characterisation of liver tumours. The purpose of this study was to assess the ability of contrast enhanced phase inversion ultrasound (PIUS), a new highly sensitive contrast specific technique, performed during the liver specific phase of Levovist, to differentiate between benign and malignant lesions of the liver.>Patients and methods: A total of 174 patients with histologically proven liver tumours were prospectively examined with conventional B mode ultrasound and two minutes after intravenous bolus injection of SHU 508A (Levovist). The examination technique comprised: Siemens Sonoline Elegra, phase inversion harmonic imaging (ECI); high mechanical index (1.2–1.7) using a delayed two minute post contrast scanning technique.>Results: In all patients with malignant disease, hypoechoic contrast enhancement was seen during the portal venous phase, and convincing but variably less demarcated in 13 patients with hepatocellular carcinoma compared with all patients with liver metastases. The liver tumours proved to be histologically benign in 95 patients and malignant in 79 patients. Homogenous contrast enhancement with a mainly isoechogenic appearance in the portal venous and liver specific late phase was seen in almost all patients with benign liver lesions with the exception of one patient with an inflammatory pseudotumour of the liver and five patients with abscesses. These six exceptions all demonstrated a hypoechoic appearance in the portal venous and liver specific late phase.>Discussion: The ability of unenhanced ultrasonography to characterise liver disease is known to be limited. PIUS performed during the portal venous and liver specific late phase of Levovist may differentiate between benign and malignant liver tumours in most cases, with the exception of, for example, abscesses, scars, necrosis, cysts, and calcifications, which need to be excluded clinically and by conventional B mode ultrasonography.
机译:>目的:据报道超声在表征肝肿瘤方面相对不可靠。这项研究的目的是评估对比增强相转化超声(PIUS)的能力,这项新的高敏感度对比特异性技术是在Levovist的肝脏特异性期进行的,以区分肝脏的良性和恶性病变。 >患者和方法:在常规推注B超和静脉推注SHU 508A(Levovist)两分钟后,对174例经组织学证实为肝肿瘤的患者进行了前瞻性检查。检验技术包括:西门子Sonoline Elegra,相位反转谐波成像(ECI);使用延迟两分钟造影剂扫描技术后获得较高的机械指数(1.2–1.7)。>结果:在所有恶性疾病患者中,在门静脉期均观察到低回声造影增强,但令人信服,但变化不大与所有肝转移患者相比,在13例肝细胞癌患者中划定了界限。肝肿瘤在组织学上被证明是良性的,有95例,恶性的有79例。在几乎所有的良性肝病变患者中,均观察到均一的造影剂增强,其主要表现为门静脉和肝特异性晚期,除了一名患有炎性假性肿瘤的患者和五名脓肿的患者。这六个例外均在门静脉和肝特异性晚期表现出低回声的外观。>讨论:众所周知,超声未增强表征肝脏疾病的能力是有限的。在大多数情况下,在Levovist的门静脉和肝特异性晚期阶段进行的PIUS可能会区分良性和恶性肝肿瘤,例如脓肿,疤痕,坏死,囊肿和钙化除外,需要临床排除并通过常规B型超声检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号